Edwards Lifesciences Corporation (EW) Gross Margin
- Gross margin · 12 months: Value 77.84%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 77.84% | Gross profit / revenue. Period ending 2026-06-30. $5.07B ÷ $6.51B × 100 ≈ 77.84% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 5.07B USD | Gross Profit |
| Revenue | 6.51B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 1.44B USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $5.07B | $6.51B | $1.44B | 77.84% |
| 2026-03-31 | $4.91B | $6.30B | $1.40B | 77.87% |
| 2025-12-31 | $4.73B | $6.07B | $1.33B | 78.01% |
| 2025-09-30 | $4.60B | $5.88B | $1.28B | 78.19% |
| 2025-06-30 | $4.48B | $5.69B | $1.20B | 78.87% |
| 2025-03-31 | $4.39B | $5.52B | $1.13B | 79.50% |
| 2024-12-31 | $4.32B | $5.44B | $1.12B | 79.46% |
| 2024-09-30 | $4.84B | $6.31B | $1.48B | 76.60% |
| 2024-06-30 | $4.74B | $6.20B | $1.47B | 76.38% |
| 2024-03-31 | $4.71B | $6.14B | $1.44B | 76.63% |
| 2023-12-31 | $4.63B | $6.00B | $1.38B | 77.02% |
| 2023-09-30 | $4.54B | $5.82B | $1.28B | 77.99% |
| 2023-06-30 | $4.47B | $5.66B | $1.18B | 79.07% |
| 2023-03-31 | $4.39B | $5.50B | $1.11B | 79.81% |
| 2022-12-31 | $4.30B | $5.38B | $1.08B | 79.93% |
| 2022-09-30 | $4.23B | $5.36B | $1.13B | 78.90% |
| 2022-06-30 | $4.17B | $5.36B | $1.19B | 77.78% |
| 2022-03-31 | $4.10B | $5.36B | $1.25B | 76.58% |
| 2021-12-31 | $3.98B | $5.23B | $1.25B | 76.13% |
| 2021-09-30 | $3.86B | $5.09B | $1.24B | 75.74% |
| 2021-06-30 | $3.72B | $4.93B | $1.21B | 75.53% |
| 2021-03-31 | $3.37B | $4.47B | $1.11B | 75.22% |
| 2020-12-31 | $3.31B | $4.39B | $1.08B | 75.36% |
| 2020-09-30 | $3.30B | $4.37B | $1.07B | 75.50% |
| 2020-06-30 | $3.24B | $4.32B | $1.08B | 74.97% |
| 2020-03-31 | $3.34B | $4.48B | $1.15B | 74.40% |
| 2019-12-31 | $3.23B | $4.35B | $1.11B | 74.37% |
| 2019-09-30 | $3.09B | $4.15B | $1.06B | 74.40% |
| 2019-06-30 | $2.97B | $3.96B | $995.40M | 74.89% |
| 2019-03-31 | $2.88B | $3.82B | $937.60M | 75.46% |
| 2018-12-31 | $2.78B | $3.72B | $939.40M | 74.77% |
| 2018-09-30 | $2.69B | $3.63B | $940.00M | 74.13% |
| 2018-06-30 | $2.62B | $3.55B | $928.40M | 73.84% |
| 2018-03-31 | $2.55B | $3.45B | $893.30M | 74.08% |
| 2017-12-31 | $2.56B | $3.44B | $875.30M | 74.52% |
| 2017-09-30 | $2.46B | $3.31B | $853.20M | 74.26% |
| 2017-06-30 | $2.39B | $3.23B | $841.30M | 73.97% |
| 2017-03-31 | $2.32B | $3.15B | $832.70M | 73.56% |
| 2016-12-31 | $2.17B | $2.96B | $797.40M | 73.09% |
| 2016-09-30 | $2.11B | $2.87B | $760.10M | 73.49% |
| 2016-06-30 | $2.04B | $2.74B | $705.40M | 74.29% |
| 2016-03-31 | $1.94B | $2.60B | $661.50M | 74.56% |
| 2015-12-31 | $1.88B | $2.49B | $617.20M | 75.25% |
| 2015-09-30 | $1.84B | $2.44B | $601.70M | 75.35% |
| 2015-06-30 | $1.81B | $2.43B | $623.10M | 74.38% |
| 2015-03-31 | $1.78B | $2.39B | $615.70M | 74.25% |
| 2014-12-31 | $1.70B | $2.32B | $625.60M | 73.07% |
| 2014-09-30 | $1.63B | $2.24B | $614.80M | 72.56% |
| 2014-06-30 | $1.55B | $2.13B | $574.90M | 73.00% |
| 2014-03-31 | $1.52B | $2.07B | $547.30M | 73.58% |
| 2013-12-31 | $1.52B | $2.05B | $522.40M | 74.46% |
| 2013-09-30 | $1.52B | $2.02B | $502.70M | 75.11% |
| 2013-06-30 | $1.49B | $1.97B | $484.70M | 75.42% |
| 2013-03-31 | $1.45B | $1.94B | $489.50M | 74.73% |
| 2012-12-31 | $1.41B | $1.90B | $494.60M | 73.96% |
| 2012-09-30 | $1.33B | $1.82B | $488.40M | 73.15% |
| 2012-06-30 | $1.28B | $1.78B | $502.30M | 71.85% |
| 2012-03-31 | $1.23B | $1.73B | $500.30M | 71.14% |
| 2011-12-31 | $1.19B | $1.68B | $489.80M | 70.82% |
| 2011-09-30 | $1.16B | $1.64B | $483.70M | 70.52% |
| 2011-06-30 | $1.12B | $1.58B | $453.90M | 71.22% |
| 2011-03-31 | $1.08B | $1.51B | $426.50M | 71.77% |
| 2010-12-31 | $1.04B | $1.45B | $408.30M | 71.78% |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2010-03-31 | $947.70M | $1.35B | (m) | 70.28% |
| 2009-12-31 | $922.30M | $1.32B | $399.10M | 69.80% |
| 2009-09-30 | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) |
| 2008-12-31 | $818.10M | $1.24B | $419.60M | 66.10% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |